Octagon Capital Advisors’s Structure Therapeutics GPCR Stock Holding History

Octagon Capital Advisors’s Portfolio GPCR Stock Details GPCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-115,000	Closed	-$3.22M	–	30
2025 Q3	$3.22M	Buy	+115,000	New	+$2.29M	0.49%	26
2024 Q4	–	Sell	-1,198,000	Closed	-$52.6M	–	40
2024 Q3	$52.6M	Buy	1,198,000 +57,940	+5%	+$2.24M	8.18%	3
2024 Q2	$44.8M	Buy	1,140,060 +633,456	+125%	+$26M	7.04%	3
2024 Q1	$21.7M	Buy	506,604 +92,604	+22%	+$3.9M	2.6%	11
2023 Q4	$16.9M	Buy	+414,000	New	+$23.7M	2.7%	10
2023 Q3	–	Sell	-75,000	Closed	-$3.12M	–	42
2023 Q2	$3.12M	Sell	75,000 -18,692	-20%	-$524K	0.43%	30
2023 Q1	$2.23M	Buy	+93,692	New	+$2.2M	0.32%	31

Other funds holding GPCR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Octagon Capital Advisors's GPCR Position: Q4 2025 in Review

Octagon Capital Advisors sold out of Structure Therapeutics (GPCR) in Q4 2025, closing a stake of 115,000 shares — an estimated $3.22M sold.

Octagon Capital Advisors first reported a position in GPCR in Q1 2023 and held it in 7 quarters. The position peaked at $52.6M in Q3 2024. 197 funds tracked by Wall St. Rank hold GPCR as of Q4 2025.

Octagon Capital Advisors reported no remaining Structure Therapeutics position as of Q4 2025 after selling out during the quarter.
Octagon Capital Advisors sold 115,000 Structure Therapeutics shares in Q4 2025, an estimated $3.22M.
Octagon Capital Advisors first reported a position in Structure Therapeutics in Q1 2023 and held it in 7 quarters.
Octagon Capital Advisors's Structure Therapeutics position peaked at $52.6M in Q3 2024.
197 funds tracked by Wall St. Rank held Structure Therapeutics as of Q4 2025.

Based on Octagon Capital Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.